TREATMENT OF DISEASES BY EPIGENETIC REGULATION

1 . A method of inhibiting BET (bromodomain and extra terminal domain protein) proteins comprising administering to the subject in need thereof, a therapeutically effective amount of at least one compound of Formula I:

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is selected from N and CRa 3 ;

V is selected from N and CRa 4 ;

W is selected from N and CH;

X is selected from OH, SH, NH 2 , S(O)H, S(O) 2 H, S(O) 2 NH 2 , S(O)NH 2 , NHAc, and NHSO 2 Me;

Ra 1 , Ra 3 , and Ra 4 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, and halogen;

Ra 2 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, amino, amide, and halogen;

Rb 3 and Rb 5 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and C 1 -C 6 alkoxy;

provided that at least one of Ra 1 , Ra 2 , Ra 3 , and Ra 4 is not hydrogen.

2 . The method according to claim 1 , wherein:

Q is CRa 3 ;

X is selected from OH, NH 2 , S(O) 2 NH 2 , NHAc, and NHSO 2 Me;

Ra 1 is selected from C 1 -C 6 alkoxy;

Ra 2 is selected from hydrogen, C 1 -C 6 alkoxy, amino, amide, and C 1 -C 6 alkyl;

Ra 3 and Ra 4 are independently selected from hydrogen and C 1 -C 6 alkoxy;

Rb 3 and Rb 5 are independently selected from C 1 -C 6 alkyl and halogen.

3 . The method according to claim 2 , wherein:

Ra 3 is selected from hydrogen, methoxy,

wherein

n is 0, 1, 2, or 3;

R 1 , R 1 ′, R 2 , and R 2 ′ are independently selected from hydrogen, C 1 -C 3 alkyl, cyclopropyl, and halogen wherein if n is 1, then R 2 and R 2 ′, R 1 and R 1 ′, R 1 and R 2 ′, or R 2 and R 1 ′ may form a double bond, wherein said double bond can be cis, trans, or a mixture thereof;

Rx is selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and aryl; and

Rn 1 and Rn 2 are independently selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and aryl.

4 . The method according to claim 2 , wherein:

Ra 3 is selected from hydrogen, methoxy,

wherein

n is 1, 2, or 3;

R 5 is selected from C 1 -C 6 alkyl substituted with one or more groups selected from methyl, phenyl, and pyridinyl; and

R 6 and R 7 are independently selected from unsubstituted C 1 -C 6 alkyl.

5 . The method according to claim 4 , wherein Ra 3 is selected from hydrogen, methoxy, 2-methoxy-ethoxy, 2-dimethylamino-ethoxy, 2-benzyloxy-ethoxy, and 2-(pyridin-3-ylmethoxy)ethoxy.

6 . The method according to claim 2 , wherein Ra 4 is selected from hydrogen and unsubstituted C 1 -C 6 alkoxy.

7 . The method according to claim 6 , wherein Ra 4 is selected from hydrogen and methoxy.

8 . The method according to claim 2 , wherein X is OH.

9 . The method according to claim 2 , wherein:

Ra 1 is selected from methoxy,

wherein

n is 0, 1, 2, or 3;

R 1 , R 1 ′, R 2 , and R 2 ′ are independently selected from hydrogen, C 1 -C 3 alkyl, cyclopropyl, and halogen wherein if n is 1, then R 2 and R 2 ′, R 1 and R 1 ′, R 1 and R 2 ′, or R 2 and R 1 ′ may form a double bond, wherein said double bond can be cis, trans, or a mixture thereof;

Rx is selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and aryl; and

Rn 1 and Rn 2 are independently selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and aryl.

10 . The method according to claim 2 , wherein:

Ra 1 is selected from methoxy,

n is 1, 2, or 3; and

R 5 , R 6 and R 7 are independently selected from unsubstituted C 1 -C 6 alkyl.

11 . The method according to claim 10 , wherein Ra 1 is selected from methoxy, 2-methoxy-ethoxy, and 2-dimethylamino-ethoxy.

12 . The method according to claim 2 , wherein:

Ra 2 is selected from hydrogen, unsubstituted C 1 -C 6 alkoxy, NHR 9 , and C 1 -C 6 alkyl substituted with heterocycle or amino; and

R 9 is selected from acyl, and heteroaryl.

13 . The method according to claim 12 , wherein Ra 2 is selected from hydrogen, methoxy, acetamido, morpholin-4-ylmethyl, pyridin-2-ylamino, (4-methylpiperazin-1-yl)methyl, and methanesulfonamido.

14 . The method according to claim 1 , wherein Rb 3 and Rb 5 are independently selected from unsubtituted C 1 -C 6 alkyl and halogen.

15 . The method according to claim 14 , wherein Rb 3 and Rb 5 are independently selected from methyl, tert-butyl, fluorine, and chlorine.

16 . The method according to claim 1 , wherein the at least one compound of Formula I is selected from:

3-(3-fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one;

3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

7-(4-hydroxy-3,5-dimethylphenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one;

2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-chloro-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one;

N-(2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)acetamide;

2-(4-hydroxy-3,5-dimethylphenyl)-6-(morpholinomethyl)quinazolin-4(3H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-6-(morpholinomethyl)quinazolin-4(3H)-one;

5-(2-dimethylamino-ethoxy)-2(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-quinazolin-4-one;

2-(4-hydroxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3H-quinazolin-4-one;

7-(2-amino-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quinazolin-4-one;

2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3H-quinazolin-4-one;

7-(2-benzyloxy-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3H-quinazolin-4-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)ethoxy]-3H-quinazolin-4-one;

7-(2-dimethylamino-ethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazol in-4-one;

2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-4-ylamino)-3H-quinazol in-4-one;

2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-2-ylamino)-3H-quinazol in-4-one;

2-(4-hydroxy-3,5-dimethylphenyl)-6-(4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one;

N-((2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)methanesulfonamide, and

tatutomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

17 . A method of inhibiting BET (bromodomain and extra terminal domain protein) proteins comprising administering a therapeutically effective amount of at least one compound of Formula II:

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

P is selected from N and CRa 1 ;

V is selected from N and CH;

W is selected from N and CH;

X is selected from O, S, CH 2 , and NH;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, and halogen;

Rb 3 and Rb 5 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, halogen, and amino;

Rd is selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 3 -C 6 cycloalkyl, wherein Rd may be connected to Rb 3 or Rb 5 to form a heterocycle,

provided that

at least one of Ra 1 and Ra 3 is not hydrogen; and

if —XRd is —OCH 2 CH 2 OH, then Rb 3 is not pyrrolidine.

18 . The method according to claim 17 , wherein:

P is CRa 1 ;

Ra 1 is selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and halogen;

Ra 3 is independently selected from hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, and halogen; and

Rb 3 and Rb 5 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, halogen, and amino.

19 . The method according to claim 18 , wherein Ra 1 is selected from unsubstituted C 1 -C 6 alkyl and unsubstituted C 1 -C 6 alkoxy.

20 . The method according to claim 19 , wherein Ra 1 is selected from methyl, ethyl, methoxy, and ethoxy.

21 . The method according to claim 18 , wherein:

Ra 3 is selected from selected from hydrogen, methoxy, unsubstituted C 1 -C 6 alkyl, halogen, and

n is 1, 2, or 3; and

R 5 is C 1 -C 6 alkyl substituted with phenyl or heteroaryl.

22 . The method according to claim 21 , wherein Ra 3 is selected from selected from hydrogen, methoxy, chlorine, fluorine, isopropoxy, methyl, 2-benzyloxy-ethoxy, and 2-(pyridin-3-ylmethoxy)ethoxy.

23 . The method according to claim 18 , wherein:

Rd is selected from C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl,

m is selected from 1, 2, or 3;

R 1 , R 1 ′, R 2 , and R 2 ′ are independently selected from hydrogen, fluorine, C 1 -C 6 alkyl, hydroxyl, —NH 2 , and C 1 -C 6 alkoxy wherein R 2 and R 2 ′ may be eliminated to form a double bond;

Y is selected from OH, SH, NH 2 , -Oalkyl, -Oaryl, —CH 2 aryl, —C(O)NHalkyl, —C(O)N(alkyl) 2 , —C(O)NHaryl, —NHacyl, —NHalkyl, —NHS(O) 2 alkyl, —N(alkyl) 2 , —NHS(O) 2 N(alkyl) 2 , —NHCN, and —NHC(O)N(alkyl) 2 , —NHheterocyclyl, and heterocyclyl; and

Rd may be connected to Rb 3 or Rb 5 to form a heterocycle,

provided that for —N(alkyl) 2 the alkyl chains cannot be joined to form an aryl or heterocyclic ring.

24 . The method according to claim 23 , wherein Rd is connected to Rb 3 or Rb 5 to form a heterocycle selected from substituted furanyl or substituted pyrrolyl.

25 . The method according to claim 24 , wherein said heterocycle is selected from 2-hydroxymethyl-furan-5-yl or 2-(4,5-dihydro-1H-pyrrol-2-yl)ethanol.

26 . The method according to claim 18 , wherein X-Rd is selected from 2-hydroxy-2-methylpropoxy, 2-hydroxyethoxy, methoxy, benzyloxyethoxy, 2,3-dihydroxypropoxy, aminocarbonylethoxy, methylaminocarbonylethoxy, (4-methoxyphenyl)aminocarbonylethoxy, benzylaminocarbonylethoxy, 4-hydroxybutoxy, (5-phenyl-4H-[1,2,4]triazol-3-ylamino)ethoxy, (3-methyl-[1,2,4]oxadiazol-5-ylamino)ethoxy, methylcarbonylaminoethoxy, methylcarbonylaminomethyl, (2,2,2-trifluoro-ethylamino)ethoxy, methanesulfonylaminoethoxy, isobutyrylaminoethoxy, methylaminoethoxy, isopropylsulfonylaminoethoxy, methylcarbonylaminoethoxy, dimethylaminoethoxy, N-(2-hydroxyethyl)-N-methylacetamide, formamide-N-2-ethoxy, methylformamide-N-2-ethoxy, dimethylsulfonylaminoethoxy, cyanoaminoethoxy, (5-methylisoxazol-3-ylamino)ethoxy, (pyrimidin-2-ylamino)ethoxy, (isoxazol-3-ylamino)ethoxy, (4,6-dimethoxypyrimidin-2-ylamino)ethoxy, 3-hydroxypropyl, and 2-hydroxyethyl.

27 . The method according to claim 26 , wherein X-Rd is selected from hydroxyethoxy, methylcarbonylaminoethoxy, (4-methoxyphenyl)aminocarbonylethoxy, and isobutyrylaminoethoxy.

28 . The method according to claim 17 , wherein the at least one compound of Formula II is selected from:

3-(4-(2-hydroxy-2-methylpropoxy)-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

N-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)acetamide;

2-(4-(2-(benzyloxy)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylpyrido[2,3-d]pyrimidin-4(3H)-one;

5,7-difluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

5,7-dichloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-diisopropoxy-3H-quinazol in-4-one;

2-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;

2-[4-(2-hydroxy-ethoxy)-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;

2-[4-(2-hydroxy-ethoxy)-naphthalen-1-yl]-5,7-dimethoxy-3H-quinazolin-4-one;

2-(2-hydroxymethyl-benzofuran-5-yl)-5,7-dimethoxy-3H-quinazolin-4-one;

7-(2-benzyloxy-ethoxy)-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5-methoxy-3H-quinazolin-4-one;

7-(2-benzyloxy-ethoxy)-2-(2-hydroxymethyl-benzofuran-5-yl)-5-methoxy-3H-quinazolin-4-one;

2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy]-acetamide;

2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy]-N-methyl-acetamide;

2-[4-(5,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-2,6-dimethyl-phenoxy]-N-(4-methoxy-phenyl)-acetamide;

N-benzyl-2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy]acetamide;

2-[4-(4-hydroxy-butoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5-methoxyquinazolin-4(3H)-one;

7-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-Dimethoxy-2-{3-methyl-4-[2-(5-phenyl-4H-[1,2,4]triazol-3-ylamino)-ethoxy]-phenyl}-3H-quinazolin-4-one;

2-{3,5-Dimethyl-4-[2-(3-methyl-[1,2,4]oxadiazol-5-ylamino)-ethoxy]-phenyl}-5,7-dimethoxy-3H-quinazolin-4-one;

N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethyl-phenoxy]-ethyl}-acetamide;

N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylbenzyl)acetamide;

N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethyl-benzyl]-acetamide;

2-{3,5-Dimethyl-4-[2-(2,2,2-trifluoro-ethylamino)-ethoxy]-phenyl}-5,7-dimethoxy-3H-quinazolin-4-one;

N-{2-[4-(6,8-Dimethoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2,6-dimethyl-phenoxy]-ethyl}-formamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)methanesulfonamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-4-methoxybenzamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)acetamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isobutyramide;

2-(3,5-dimethyl-4-(2-(methylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)propane-2-sulfonamide;

2-(4-(2-(isopropylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)ethyl)acetamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)ethyl)isobutyramide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylphenoxy)ethyl)methanesulfonamide;

2-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-N-methylacetamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)formamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-N-methylformamide;

N-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)dimethylamino-N-sulfonamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)cyanamide;

2-(3,5-dimethyl-4-(2-(5-methylisoxazol-3-ylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrimidin-2-ylamino)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(isoxazol-3-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(4,6-dimethoxypyrimidin-2-ylamino)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-[4-(3-hydroxy-propyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-3H-quinazolin-4-one;

2-[4-(3-hydroxy-propyl)-3-methoxy-phenyl]-5,7-dimethoxy-3H-quinazolin-4-one; and

2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one, and

tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof.

29 . The method according to claim 1 , wherein the therapeutically effective amount of the compound is administered with at least one pharmaceutically acceptable carrier in a pharmaceutically acceptable composition.

30 . The method according to claim 17 , wherein the therapeutically effective amount of the compound is administered with at least one pharmaceutically acceptable carrier in a pharmaceutically acceptable composition.

31 . The method according to claim 1 , wherein the compound of Formula 1 is administered to treat or prevent a cancer selected from cancers that exhibit c-myc overexpression, cancers that overexpress n-myc, cancers that that rely on the recruitment of p-TEFb to regulate activated oncogenes, Burkitt's lymphoma, acute myelogenous leukemia, multiple myeloma, aggressive human medulloblastoma, hematological, epithelial cancers, lung cancers, breast cancers, colon carcinomas, midline carcinomas, mesenchymal tumors, hepatic tumors, renal tumors, and neurological tumors.

32 . The method of claim 31 , wherein the compound of Formula I is administered in combination with another anti-cancer agent selected from the group consisting of bortezomib, thalidomide, dexamethasone, 5-azacitidine, decitabine, vorinostat, cyclophosphamide, a PI3K or mTOR inhibitor, rapamycin or a rapamycin analog, a gamma secretase inhibitor, an AMPK inducer, metformin, phenformin, an ornithine decarboxylase inhibitor, and difluoromethylornithine.